Ironwood Pharmaceuticals stock reports higher 2026 revenue guidance
Published on 10/07/2026 at 02:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ironwood Pharmaceuticals (ISIN US46333X1081) was last at USD 3.63 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 0.55 percent from the prior close. The company enters its next reporting phase with higher 2026 revenue guidance and a key clinical program advancing.
Guidance rises after Q2
Benzinga reported Q2 2026 revenue of USD 113 million, GAAP net income of USD 51.3 million and adjusted EBITDA of USD 83 million. Management raised full-year revenue guidance to USD 460 million-USD 485 million and expects adjusted EBITDA above USD 310 million.
The guidance change matters because it lifts both ends of the prior USD 450 million-USD 475 million range by USD 10 million. The latest quarter also produced operating cash flow of USD 58.3 million, giving Ironwood additional financial capacity while it funds clinical development.
Linzess drives the outlook
Linzess U.S. net sales reached USD 282.3 million in Q2 2026, up 14 percent year over year, according to Benzinga. First-half Linzess U.S. sales reached USD 555 million, a 44 percent year-over-year increase, while the company raised its full-year Linzess sales outlook to USD 1.15 billion-USD 1.20 billion.
The commercial engine remains central to the investment case. Ironwood is also advancing the STARS 2 confirmatory Phase 3 trial for apraglutide, with enrollment activity making execution and development spending important factors for the second half of 2026.
Analysts see a higher target
Ticker Nerd lists four analysts covering Ironwood, with two Buy ratings, two Hold ratings and no Sell ratings. The median 12-month price target is USD 5.35, with a low of USD 3.70 and a high of USD 10.00.
Using the October 6 price of USD 3.63, the median target lies 47.1 percent above the stock. That spread reflects the market's focus on continued Linzess growth, while the wide USD 3.70-USD 10.00 target range shows substantial disagreement about the value of the pipeline.
Stock remains below its yearly high
IRWD's market capitalization was USD 597.5 million on October 6, 2026, and volume reached 1,867,044 shares. The stock's 52-week range was USD 1.41-USD 5.78, placing the last price USD 2.15 below the yearly high.
Ironwood's next earnings date is October 29, 2026, according to Makkler. The company develops and commercializes gastrointestinal and rare-disease therapies, with LINZESS and apraglutide defining the near-term operating and clinical picture.
Ironwood Pharmaceuticals stock facts
- Company: Ironwood Pharmaceuticals, Inc.
- ISIN: US46333X1081
- Ticker: IRWD
- Trading venue: NASDAQ
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 3.63
- Market capitalization: USD 597.5 million (as of October 6, 2026)
- 52-week range: USD 1.41-USD 5.78 (as of October 6, 2026)
- Sector / Industry: Health Technology / Biotechnology: Pharmaceutical Preparations
Upcoming dates for Ironwood Pharmaceuticals stock
- October 29, 2026: Quarterly earnings report
